menu
    • menu

    Company profile for Lantern Pharma

    NEW Drugs in Dev: 7
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lantern Pharma is a clinical stage oncology biotech that leverages Artificial Intelligence and Machine Learning to deeply understand genomic data. Lantern in-licenses and develops therapies using genomic data, Machine Learning, and computational biology modeling to identify the patient groups most likely to respond to a therapy, and to clarify the potential underlying mechanism(s) of action.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lantern PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Kearny Point, Kearny, New Jersey 07032, US
    Telephone
    Telephone
    917-810-9412
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lanternpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lanternpharma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lantern Pharma Presents At 7th Glioblastoma Drug Summit
    Lantern Pharma Presents At 7th Glioblastoma Drug Summit

    10 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260210506555/en/Lantern-Pharma-to-Present-at-the-7th-Glioblastoma-Drug-Development-Summit-in-Boston-on-February-17-19-2026

    BUSINESSWIRE
    10 Feb 2026
    Share Share
    FDA Grants Orphan Drug Status to LP-284 for Soft Tissue Sarcoma
    FDA Grants Orphan Drug Status to LP-284 for Soft Tissue Sarcoma

    20 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260120542667/en/Lantern-Pharmas-LP-284-Receives-FDA-Orphan-Drug-Designation-for-Soft-Tissue-Sarcomas

    BUSINESSWIRE
    20 Jan 2026
    Share Share
    Lantern Sets Up A.I. Center In India To Boost RADR Platform
    Lantern Sets Up A.I. Center In India To Boost RADR Platform

    12 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260112478486/en/Lantern-Pharma-Announces-Establishing-an-A.I.-Center-of-Excellence-in-India-to-Industrialize-the-RADR-Platform-and-Accelerate-Global-Development-Opportunities-with-BioPharma-Companies

    BUSINESSWIRE
    12 Jan 2026
    Share Share
    Lantern Pharma Advances LP-184 Trials with Positive Phase 1a Data
    Lantern Pharma Advances LP-184 Trials with Positive Phase 1a Data

    03 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-03/lantern-pharma-reports-additional-positive-lp-184-phase-1a-results-showing-durable-disease-control-i

    PHARMIWEB
    03 Dec 2025
    Share Share
    Lantern Pharma Reveals Q3 2025 Financials And Business Updates
    Lantern Pharma Reveals Q3 2025 Financials And Business Updates

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113233259/en/Lantern-Pharma-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    Lantern Pharma To Release Q3 2025 Financial Results On Nov. 13
    Lantern Pharma To Release Q3 2025 Financial Results On Nov. 13

    06 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251106738628/en/Lantern-Pharma-to-Report-Third-Quarter-2025-Operating-Financial-Results-on-November-13th-2025-at-900-a.m.-ET

    BUSINESSWIRE
    06 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search